Pfizer sues Metsera, Novo Nordisk
Digest more
There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...
Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...
The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...
Novo Nordisk is striving to maintain Medicaid reimbursement for its obesity drug, Wegovy, as several U.S. states face ...
Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...
Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...
Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo ...
Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback